<DOC>
	<DOCNO>NCT02334800</DOCNO>
	<brief_summary>This phase 1 study describe plasma pharmacokinetics single oral 75mg dose palbociclib administer healthy volunteer , subject mild , moderate , severely impaired hepatic function .</brief_summary>
	<brief_title>A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib</brief_title>
	<detailed_description>This 4-cohort single period study . The four cohort consist healthy volunteer , subject mild , moderate , severely impaired hepatic function . Each cohort receive treatment consist single oral 75mg dose palbociclib administer food . Serial PK sample draw 120 hour post dose cohort consist healthy volunteer , continue 192 hour post-dose cohort hepatic impairment subject .</detailed_description>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<criteria>Body Mass Index ( BMI ) 18 40 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) Evidence personally sign date informed consent document indicate subject inform pertinent aspect study Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure Any condition possibly affect drug absorption ( eg , gastrectomy ) A positive urine drug screen Pregnant female subject ; breastfeed female subject ; female subject childbearing potential ; male subject partner currently pregnant ; male subject childbearing potential unwilling unable use highly effective method contraception duration study 90 day last dose investigational product History sensitivity heparin heparininduced thrombocytopenia Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose Unwilling unable comply Lifestyle Guidelines describe protocol Use tobacco nicotine product excess 5 cigarette per day ( equivalent ) History sensitivity palbociclib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Palbociclib , PD-0332991 , Hepatic Impairment</keyword>
</DOC>